President Obama is proposing "a major new initiative to develop drugs tailored to the genetic characteristics of individual patients, but he expresses deep concern about the costs of such specialty medicines for consumers and for the Medicare program," reports Robert Pear in April 27 New York Times. ...continue reading "Obama Proposes That Medicare Be Given the Right to Negotiate the Cost of Drugs"
Advocating for advanced prostate cancer patients in Scotland, Alister Walker, Chairman and volunteer in Perth & Kinross Prostate Cancer Support Group, writes in the Scottish newspaper The Herald:
"Last week we read the good news that Moderator-Designate of the General Assembly of the Church of Scotland, the Reverend Dr Angus Morrison, has overcome the disease (Church leader in cancer warning , The Herald, April 23). With prostate cancer so often being symptomless in its early stages he is right to urge other men to consider speaking to their GP about the disease. This is particularly important for men aged over 50, black men and men whose father or brother has had the disease - who are at a higher risk. ...continue reading "Abiraterone rejection in Scotland must be overturned, Prostate Cancer advocate says"
April 29, 2015. Many patients with higher-risk localized prostate cancer are treated with external beam radiation or with brachytherapy (seed implants). A clinical trial conducted by Dr James Miller (right) of Vancouver, Canada has found that patients receiving permanent implant brachytherapy "seeds" plus a boost of radiation have a better chance of long-term survival than those treated with higher dose-escalated external beam radiotherapy but without the implants.
Men receiving the radioactive "seeds" were more likely to be cancer-free five to nine years later. ...continue reading "Brachytherapy combination improves PSA-free survival for patients with higher-risk localized prostate cancer, trial finds"
A normal prostate wedges neatly into the crowded multifunctional area of a man's lower pelvis.
The prostate in men, like the breast in a woman, is a gland that produces and secretes fluid and controls the fluid's flow.
Implantable device could allow doctors to test cancer drugs in patients before prescribing
PSA Rising-- April 24, 2015, More than 100 drugs have been approved in the USA to treat cancer, but predicting which ones will help an individual patient is an inexact science. Patients may undergo weeks of noxious side effects before scans reveal that for this patient a particular drug is not working--even though it works for the patient in the next chair. A new implantable device, about the size of a grain of rice, may change that. ...continue reading "A Step Toward Personalized Chemotherapy"
Dr Leszek Kotula, co-author of the WAVE1 study, explains in this video from 2013 how basic science research in his lab at Upstate Medical University in Syracuse, NY will benefit prostate cancer patients with better diagnostic and treatment options.
April 7, 2015. Researchers at Upstate Medical University, NY and Harvard University have linked the loss of key gene, WAVE1, to a lethal form of prostate cancer. They found that in patients who were treated for prostate cancer, alterations in the WAVE1 gene were associated with a shorter remission.
Welcome! If you're in the PCa boat, we're sorry, but glad that you're reaching out for information from a patient-centered support community.
This year, 2015, according to reliable statistics, some 220,800 men will be diagnosed with prostate cancer and some 27,540 men will die of this disease. If you read medical news, you'll find these and related statistics intoned in virtually every research article. ...continue reading "If you’re new here . . ."
April 23, 2015. African American men have the highest rates of prostate cancer incidence and mortality in the United States. For the past twenty years cancer researchers have worried about this and researched various causal factors. Now a large study suggests obesity may play an important role in what specialists in disparities in prostate cancer risk are calling the "African-American race effect.